Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Core Viewpoint - Mesoblast Limited reported a significant revenue growth of 60% in Q4 2025, driven by Ryoncil sales, and secured a new $125 million financing facility to enhance its financial flexibility and support strategic initiatives [1][3][5]. Financial Performance - The company achieved gross revenue of $35.1 million from Ryoncil sales for the quarter ended December 31, 2025, marking a 60% increase compared to the previous quarter [1]. - The new financing facility of $125 million is a five-year interest-only arrangement that lowers the overall cost of capital and allows for repayment flexibility without penalties [4]. Product Development - Ryoncil is the first FDA-approved mesenchymal stromal cell product for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD) and is set to enter a pivotal trial for adults with SR-aGvHD, a market three times larger than the pediatric segment [2][8]. - The company is also developing additional therapies for other inflammatory diseases and conditions, including biologic-resistant inflammatory bowel disease and heart failure [8]. Strategic Partnerships - The strong balance sheet and revenue growth provide Mesoblast with greater flexibility to pursue strategic partnerships and expand the label for Ryoncil [5]. - The company has established commercial partnerships in key markets including Japan, Europe, and China [8]. Intellectual Property - Mesoblast holds a robust global intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection until at least 2044 in major markets [9].